MX382056B - P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación. - Google Patents

P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación.

Info

Publication number
MX382056B
MX382056B MX2017011392A MX2017011392A MX382056B MX 382056 B MX382056 B MX 382056B MX 2017011392 A MX2017011392 A MX 2017011392A MX 2017011392 A MX2017011392 A MX 2017011392A MX 382056 B MX382056 B MX 382056B
Authority
MX
Mexico
Prior art keywords
crystal form
toluenesulfonate
preparation
kinase inhibitor
mek kinase
Prior art date
Application number
MX2017011392A
Other languages
English (en)
Other versions
MX2017011392A (es
Inventor
Guaili Wu
Junlei Jia
Lin Bian
Xiaohui Gao
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2017011392A publication Critical patent/MX2017011392A/es
Publication of MX382056B publication Critical patent/MX382056B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe un p-toluensulfonato para un inhibidor de MEK cinasa, y una forma de cristal del mismo y un método de preparación del mismo. De manera específica, se describe p-toluensulfonato de 2-((2-fluorine-4-yodofenil)amino)-1-metil-4-((6-metilpiridin-3-grupo)oxigrupo)-6-carbonil-1,6-dihidropiridin-3-formamida (un compuesto representado por la fórmula (I)), y una forma de cristal I y un método de preparación del mismo. La forma de cristal I obtenida del compuesto representada por la fórmula (I) tiene buena estabilidad de forma de cristal y estabilidad química, y un solvente de cristalización usado tiene baja toxicidad y bajo residuo y puede usarse mejor en el tratamiento clínico. (ver Fórmula).
MX2017011392A 2015-03-27 2016-03-08 P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación. MX382056B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510141303 2015-03-27
PCT/CN2016/075853 WO2016155473A1 (zh) 2015-03-27 2016-03-08 一种mek激酶抑制剂的对甲苯磺酸盐、其结晶形式及制备方法

Publications (2)

Publication Number Publication Date
MX2017011392A MX2017011392A (es) 2018-01-15
MX382056B true MX382056B (es) 2025-03-13

Family

ID=57005438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011392A MX382056B (es) 2015-03-27 2016-03-08 P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su método de preparación.

Country Status (12)

Country Link
US (2) US10118911B2 (es)
EP (1) EP3275866B1 (es)
JP (1) JP2018509407A (es)
KR (1) KR20170131506A (es)
CN (1) CN106795116B (es)
AU (1) AU2016239028B2 (es)
BR (1) BR112017018580A2 (es)
CA (1) CA2978796A1 (es)
MX (1) MX382056B (es)
RU (1) RU2704251C2 (es)
TW (1) TWI705060B (es)
WO (1) WO2016155473A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041561A1 (en) 2016-11-25 2018-05-31 Jiangsu Hengrui Medicine Co., Ltd. Pyridone derivative pharmaceutical composition and preparation method thereof
TW201821408A (zh) * 2016-12-01 2018-06-16 大陸商江蘇恆瑞醫藥股份有限公司 一種吡啶酮類衍生物的製備方法及其中間體
WO2020156162A1 (zh) * 2019-01-29 2020-08-06 贝达药业股份有限公司 Mek抑制剂及其在医药上的应用
TW202114994A (zh) * 2019-07-29 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種1,6-二氫吡啶-3-甲醯胺衍生物的製備方法
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス, インコーポレイテッド 併用療法
CN118973580A (zh) 2022-04-08 2024-11-15 米拉蒂治疗股份有限公司 包含sos1抑制剂和mek抑制剂的组合疗法
CN119768393A (zh) * 2022-05-25 2025-04-04 医肯纳肿瘤学公司 Mek抑制剂和其用途
CN120441478A (zh) * 2024-02-07 2025-08-08 成都赜灵生物医药科技有限公司 一种六元内酰胺类化合物及其应用
WO2026085809A1 (zh) * 2024-10-24 2026-04-30 上海复星医药产业发展有限公司 蛋白激酶抑制剂的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1272290B (it) * 1994-06-20 1997-06-16 Avantgarde Spa Sale della l-carnitina e composizioni farmaceutiche che lo contengono per il trattamento di affezioni cutanee
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
EP2279166A1 (en) * 2008-04-22 2011-02-02 Bayer Schering Pharma Aktiengesellschaft Substituted phenoxybenzamides
EP2382216A1 (en) * 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
CN102459188A (zh) * 2009-06-15 2012-05-16 凯美隆(北京)药业技术有限公司 新型6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂
US20120238599A1 (en) * 2011-03-17 2012-09-20 Chemizon, A Division Of Optomagic Co., Ltd. Heterocyclic compounds as mek inhibitors
WO2014204263A1 (en) * 2013-06-20 2014-12-24 The Asan Foundation Substituted pyridinone compounds as mek inhibitors
EP3061747B1 (en) * 2013-10-25 2021-04-07 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof

Also Published As

Publication number Publication date
TWI705060B (zh) 2020-09-21
CN106795116A (zh) 2017-05-31
US10118911B2 (en) 2018-11-06
WO2016155473A1 (zh) 2016-10-06
RU2017134709A3 (es) 2019-07-17
CN106795116B (zh) 2019-11-01
CA2978796A1 (en) 2016-10-06
EP3275866A4 (en) 2018-08-15
RU2704251C2 (ru) 2019-10-25
AU2016239028A1 (en) 2017-09-14
US20180370948A1 (en) 2018-12-27
BR112017018580A2 (pt) 2018-04-24
RU2017134709A (ru) 2019-04-29
TW201634459A (zh) 2016-10-01
US20180118715A1 (en) 2018-05-03
AU2016239028B2 (en) 2019-09-19
EP3275866B1 (en) 2019-12-04
MX2017011392A (es) 2018-01-15
JP2018509407A (ja) 2018-04-05
EP3275866A1 (en) 2018-01-31
KR20170131506A (ko) 2017-11-29

Similar Documents

Publication Publication Date Title
MX2017011392A (es) P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
CU20170087A7 (es) Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX2016013052A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
UA113643C2 (xx) N-цикліламіди як нематоциди
CR20200177A (es) Compuestos de biheteroarilo (divisional 2015-0589)
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
MX2017002206A (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
PE20170300A1 (es) Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
EA201492223A1 (ru) Новые диазаспироциклоалканы и азаспироциклоалканы
CL2017002813A1 (es) Proceso para preparar 4-amino-piridazinas
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2018000280A (es) Oxiesteroles y metodos de uso de los mismos.
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
AR104342A1 (es) Compuesto heterocíclico
MX2018003832A (es) Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo.
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
MX2016013162A (es) Proceso para la fabricacion de medicamentos.
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2